Compare Moderna, Inc. (MRNA) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Prudential PLC — how do they compare? Moderna, Inc. trades at $137.4 (market cap $56.02B), while Prudential PLC trades at $27.1 (market cap $34.05B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Prudential PLC pays a 2.03% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PUK | |
|---|---|---|
Market Cap | $56.02B | $34.05B |
Sector | Health | Financials |
52-Week High | $174.38 | $33.61 |
52-Week Low | $22.36 | $24.98 |
Enterprise Value | $52.17B | $33.60B |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Prudential (PUK) trades at $27.42, down 1.19% with bearish technical signals but strong fundamentals including 14.52% net margin and 19.24% ROE. Recent earnings show mixed results with Q2 2026 missing expectations while maintaining revenue growth to $27.4B in 2025. The company demonstrates improved cash flow generation with $1.93B net cash flow in 2025 and continues shareholder returns through dividends.
The stock presents value with a 9.64 P/E ratio amid analyst optimism (50% buy ratings), though China regulatory risks and technical bearishness warrant caution. Long-term growth prospects in Asian markets and capital return initiatives support investment case, but investors should monitor execution of the five-year strategic reshaping plan.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
